;

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Finance > Sanofi to acquire Vigil Neuroscience in $470 million deal

Finance

Sanofi to acquire Vigil Neuroscience in $470 million deal

Published by Global Banking and Finance Review

Posted on May 22, 2025

Featured image for article about Finance

(Reuters) -Sanofi said on Thursday that it would acquire Vigil Neuroscience, a clinical-stage biotech company, for $8 per share in cash, valuing the deal at about $470 million.

(Reporting by Bipasha Dey in Bengaluru; Editing by Mohammed Safi Shamsi)

More from Finance

Explore more articles in the Finance category

EU talks to fund Ukraine with Russian assets make progress, key decisions seen Thursday

Shell greenlights US Gulf waterflood project to boost oil recovery

Exclusive-Saudi firm Midad among frontrunners to buy Lukoil's global assets, sources say

UK to review foreign interference in politics after ex-Reform member's Russia bribery case

Russia calls German broadcaster Deutsche Welle an 'undesirable organisation'

Italy plans 2.4 billion euros investment in frigates, document shows

Swedish greenhouse gas emissions on rise again after government relaxes fuels policy, data shows

Eurovision host says it will not drown out any boos during Israel's performance

From pulpit to turntables: Portugal's 'DJ Priest' brings his message to Latin America

Leonardo denies liability for helicopter crash that killed Leicester City owner

Explainer-French lawmakers race to agree 2026 budget before year-end

UK's FTSE 100 falls as oil, defence stocks weigh; domestic unemployment climbs

View All Finance Posts